期刊文献+

阿尔茨海默病诊断研究进展 被引量:12

Diagnosis of Alzheimer’s disease
原文传递
导出
摘要 阿尔茨海默病(Alzheimer’s disease,AD)是一种进行性的神经退行性疾病,病理生理学机制复杂,随着研究的深入,对疾病的表观研究也从宏观深入到分子水平。有关AD的诊断,除可根据患者日常生活中行为、性格改变外,还可借助CT、MRI、PET、脑电图等影像辅助检查发现其大脑结构及功能的变化,并可通过有创检查观察患者脑脊液、血液中某些生物分子和基因改变情况。本文就AD诊断的研究进展作一综述。 Alzheimer’s disease is a progressive neurodegenerative disease with complex pathophysiological mechanisms.The research on disease apparent has also been extended from the macro level to the molecular level.Its diagnosis relies on the brain structure/function findings on CT,MRI,PET and EEG,as well as the molecular and genetic changes in the cerebrospinal fluid by traumatic examinations,besides the changes of the patients’behaviors and personalities.This paper reviews the research progress of the diagnosis of Alzheimer’s disease.
作者 侯伟丽 马兰 HOU Weili;MA Lan(Department of Geriatrics,the Second Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
出处 《中华实用诊断与治疗杂志》 2020年第4期417-419,共3页 Journal of Chinese Practical Diagnosis and Therapy
基金 黑龙江省自然科学基金(重点项目)(ZD2018017)。
关键词 阿尔茨海默病 影像辅助检查 生物分子 基因 Alzheimer’s disease imaging biomolecule gene
  • 相关文献

参考文献7

二级参考文献42

  • 1曹雯炜,张丽,钟根龙,李焰生.美国痴呆最新药物治疗临床操作指南[J].中国卒中杂志,2008,3(6):423-429. 被引量:23
  • 2Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010[J]. J Neuropathol Exp Neurol, 2012,71 (4) : 266-273.
  • 3Vandenberghe R, Nelissen N, Salmon E, et al. Binary classification of 18F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI [ J ]. Neuroimage, 2012,64 (1) :517-525.
  • 4Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-b plaques: a prospective cohort study[J]. Lancet Neurol, 2012,11(8) : 669-678.
  • 5Rinne JO, Wong DF, Wolk DA, et al. 18F-flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid h detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies[J]. Acta Neuropathol, 2012,124 (6) :833-845.
  • 6Thurfjell L, Lotjonen J, Lundqvist R, et al. Combination of biomarkers: PET 18F-flutemetamol imaging and structural MRI in dementia and mild cognitive impairment[J]. Neurodegener Dis, 2012,10(1/4) :246-249.
  • 7Duara R, Loewenstein DA, Shen Q, et al. Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease [J]. Alzheimers Dement, 2013,9(3) :295-301.
  • 8Devanand DP, Mikhno A, Pelton GH, et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls[J]. J Geriatr Psychiatry Neurol, 2010,23 (3):185-198.
  • 9Rabinoviei GD, Rosen HJ, Alkalay A, etal. Amyloid vs FDG- PET in the differential diagnosis of AD and FTLD [J]. Neurology, 2011,77 (23) : 2034-2042.
  • 10Fagan AM, Mintun MA, Shah AR, et al. Cerehrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease [J]. EMBO Mol Med, 2009,1 (8/ 9):371-380.

共引文献458

同被引文献156

引证文献12

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部